
R&D Center
Every high-quality product is backed by robust scientific research. We have two state-of-the-art labs in China and the U.S., staffed by a team of scientists led by a fellow of the American Institute for Medical and Biological Engineering.
-
agebox Lab
Virginia, U.S.
-
Xregen Lab
Hangzhou, China
-
Clinical Trials

Agebox Lab
Founded in 2009, Agebox Lab is led by a fellow of the American Institute for Medical and Biological Engineering. The lab specializes in studying the effects of plant components on the human body and developing dietary supplements using molecular biology and precise extraction techniques.At Agebox Lab, every technology undergoes a rigorous development process, including cellular functional experiments, animal experiments, and human trials. The lab has compiled a comprehensive database of tens of thousands of functional plant extracts, covering 17 core signaling pathways in eight systems such as bone and muscle development, lipid metabolism, blood glucose regulation, uric acid metabolism, and neuroinflammation. This database includes 62 key molecular targets. Leveraging this extensive database, Agebox Lab can quickly generate optimal formulas of natural extracts for specific indications. The lab has successfully developed multiple functional dietary supplement formulas for various conditions, including ASD, depression, and ADHD.

Xregen Lab
Founded in 2021, Xregen Lab focuses on the commercialization of global formulations and the research and development of Chinese local formulations. The lab has established a comprehensive, standardized process for the commercialization of formulations. Each new formulation launched adheres to strict criteria, including safety, compliance, stability, efficacy, and manufacturability, ensuring that consumers receive truly safe and effective products.
Xregen Lab also emphasizes the abundant natural bioresources in China. In the future, we aim to leverage the world's leading biomedical technologies to develop more dietary supplements with Chinese characteristics, bringing more health products to consumers in China and worldwide.

Clinical Trials
In July 2023, the Children's Hospital of Zhejiang University School of Medicine officially announced the launch of a clinical study titled “Clinical Study of the Efficacy and Safety of Children's Dietary Supplement iKids-Growth™ in Improving Height Development in Silver-Russell Syndrome (SRS) Patients” (Clinical Trial Registration Number: ChiCTR2300071632). This study aims to explore a novel therapy for SRS children, focusing on enhancing their health and promoting height development.
-
Registration number: ChiCTR2300071632
Learn More in ICTRPEnglish Acronym:
Clinical Study of the Efficacy and Safety of iKids-Growth™ Children's Dietary Supplement in Improving Height Development in Silver-Russell Syndrome (SRS) Patients.
Affiliation of the Leader:
Children's Hospital of Zhejiang University School of Medicine.
-
Registration number: ChiCTR2400082004
Learn More in ICTRPEnglish Acronym:
iKids-Growth—SHOX-D Clinical Study.
Affiliation of the Leader:
Clinical Study of the Efficacy and Safety of iKids-Growth™ Children's Dietary Supplement in Improving Height Development in SHOX Deficiency (SHOX-D) Patients.
-
Registration number: ChiCTR2400084375
Learn More in ICTRPEnglish Acronym:
A prospective cohort study of dietary supplement iKids-Growth™ for children to improve height development in short children with slow preadolescent growth .
Affiliation of the Leader:
Children's Hospital of Nanjing Medical University.